These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 18622939)

  • 1. [Long-acting medications for the treatment of hyperkinetic disorders - a systematic review and European treatment guidelines. Part 2: a quantitative evaluation of long-acting medications].
    Banaschewski T; Coghill D; Santosh P; Zuddas A; Asherson P; Buitelaar J; Danckaerts M; Döpfner M; Faraone SV; Rothenberger A; Sergeant J; Steinhausen HC; Sonuga-Barke EJ; Taylor E
    Z Kinder Jugendpsychiatr Psychother; 2008 Mar; 36(2):97-106; quiz 106-7. PubMed ID: 18622939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Long-acting medications for the treatment of hyperkinetic disorders - a systematic review and European treatment guideline. Part 1: overview and recommendations].
    Banaschewski T; Coghill D; Santosh P; Zuddas A; Asherson P; Buitelaar J; Danckaerts M; Döpfner M; Faraone SV; Rothenberger A; Sergeant J; Steinhausen HC; Sonuga-Barke EJ; Taylor E
    Z Kinder Jugendpsychiatr Psychother; 2008 Mar; 36(2):81-94; quiz 94-5. PubMed ID: 18622938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline.
    Banaschewski T; Coghill D; Santosh P; Zuddas A; Asherson P; Buitelaar J; Danckaerts M; Döpfner M; Faraone SV; Rothenberger A; Sergeant J; Steinhausen HC; Sonuga-Barke EJ; Taylor E
    Eur Child Adolesc Psychiatry; 2006 Dec; 15(8):476-95. PubMed ID: 16680409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comment on the European guidelines for use of delayed action drugs for treatment of hyperkinetic disorders].
    Banaschewski T; Döpfner M; Rothenberger A; Steinhausen H-
    Z Kinder Jugendpsychiatr Psychother; 2008 Mar; 36(2):77-9. PubMed ID: 18622937
    [No Abstract]   [Full Text] [Related]  

  • 5. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
    Findling RL
    Clin Ther; 2008 May; 30(5):942-57. PubMed ID: 18555941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Priapism associated with the use of stimulant medications and atomoxetine for attention-deficit/hyperactivity disorder in children.
    Eiland LS; Bell EA; Erramouspe J
    Ann Pharmacother; 2014 Oct; 48(10):1350-5. PubMed ID: 24982313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sleep disturbances and ADHD medications.
    Rostain AL
    Curr Psychiatry Rep; 2007 Oct; 9(5):399-400. PubMed ID: 17915079
    [No Abstract]   [Full Text] [Related]  

  • 8. Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder: an update.
    Awudu GA; Besag FM
    Drug Saf; 2014 Sep; 37(9):661-76. PubMed ID: 25124483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative study of OROS-MPH and atomoxetine on executive function improvement in ADHD: a randomized controlled trial.
    Yang L; Cao Q; Shuai L; Li H; Chan RC; Wang Y
    Int J Neuropsychopharmacol; 2012 Feb; 15(1):15-26. PubMed ID: 22017969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Caregiver survey of pharmacotherapy to treat attention deficit/hyperactivity disorder in individuals with Williams syndrome.
    Martens MA; Seyfer DL; Andridge RR; Foster JE; McClure KE; Coury DL
    Res Dev Disabil; 2013 May; 34(5):1700-9. PubMed ID: 23500164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative treatment patterns, healthcare resource utilization and costs of atomoxetine and long-acting methylphenidate among children and adolescents with attention-deficit/hyperactivity disorder in Germany.
    Greven P; Sikirica V; Chen YJ; Curtice TG; Makin C
    Eur J Health Econ; 2017 Sep; 18(7):893-904. PubMed ID: 27817164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term quality-of-life and functioning comparison of atomoxetine versus other standard treatment in pediatric attention-deficit/hyperactivity disorder.
    Fuentes J; Danckaerts M; Cardo E; Puvanendran K; Berquin P; De Bruyckere K; Montoya A; Quail D; Escobar R
    J Clin Psychopharmacol; 2013 Dec; 33(6):766-74. PubMed ID: 23963057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trends in incidence and characteristics of children, adolescents, and adults initiating immediate- or extended-release methylphenidate or atomoxetine in the Netherlands during 2001-2006.
    van den Ban E; Souverein P; Swaab H; van Engeland H; Heerdink R; Egberts T
    J Child Adolesc Psychopharmacol; 2010 Feb; 20(1):55-61. PubMed ID: 20166797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [What's new about hyperactivity disorder in children?].
    Le Heuzey MF
    Arch Pediatr; 2008 Jul; 15(7):1249-52. PubMed ID: 18485682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cessation of attention deficit hyperactivity disorder drugs in the young (CADDY)--a pharmacoepidemiological and qualitative study.
    Wong IC; Asherson P; Bilbow A; Clifford S; Coghill D; DeSoysa R; Hollis C; McCarthy S; Murray M; Planner C; Potts L; Sayal K; Taylor E
    Health Technol Assess; 2009 Oct; 13(50):iii-iv, ix-xi, 1-120. PubMed ID: 19883527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and 1-Year Follow-Up.
    Su Y; Yang L; Stein MA; Cao Q; Wang Y
    J Child Adolesc Psychopharmacol; 2016 May; 26(4):362-71. PubMed ID: 26779845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.
    Chavez B; Sopko MA; Ehret MJ; Paulino RE; Goldberg KR; Angstadt K; Bogart GT
    Ann Pharmacother; 2009 Jun; 43(6):1084-95. PubMed ID: 19470858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder.
    Gibson AP; Bettinger TL; Patel NC; Crismon ML
    Ann Pharmacother; 2006 Jun; 40(6):1134-42. PubMed ID: 16735655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response.
    Newcorn JH; Kratochvil CJ; Allen AJ; Casat CD; Ruff DD; Moore RJ; Michelson D;
    Am J Psychiatry; 2008 Jun; 165(6):721-30. PubMed ID: 18281409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching from neurostimulant therapy to atomoxetine in children and adolescents with attention-deficit hyperactivity disorder : clinical approaches and review of current available evidence.
    Prasad S; Steer C
    Paediatr Drugs; 2008; 10(1):39-47. PubMed ID: 18162007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.